Literature DB >> 2202308

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

R Y Leavitt1, A S Fauci, D A Bloch, B A Michel, G G Hunder, W P Arend, L H Calabrese, J F Fries, J T Lie, R W Lightfoot.   

Abstract

Criteria for the classification of Wegener's granulomatosis (WG) were developed by comparing 85 patients who had this disease with 722 control patients with other forms of vasculitis. For the traditional format classification, 4 criteria were selected: abnormal urinary sediment (red cell casts or greater than 5 red blood cells per high power field), abnormal findings on chest radiograph (nodules, cavities, or fixed infiltrates), oral ulcers or nasal discharge, and granulomatous inflammation on biopsy. The presence of 2 or more of these 4 criteria was associated with a sensitivity of 88.2% and a specificity of 92.0%. A classification tree was also constructed with 5 criteria being selected. These criteria were the same as for the traditional format, but included hemoptysis. The classification tree was associated with a sensitivity of 87.1% and a specificity of 93.6%. We describe criteria which distinguish patients with WG from patients with other forms of vasculitis with a high level of sensitivity and specificity. This distinction is important because WG requires cyclophosphamide therapy, whereas many other forms of vasculitis can be treated with corticosteroids alone.

Entities:  

Mesh:

Year:  1990        PMID: 2202308     DOI: 10.1002/art.1780330807

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  421 in total

1.  Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.

Authors:  M Gencik; S Borgmann; R Zahn; E Albert; T Sitter; J T Epplen; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

Review 3.  An unusual case of multiple cranial nerve palsies in Wegener's granulomatosis.

Authors:  A D Daderian; S Chayasirisobhon
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

4.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 5.  Wegener's granulomatosis and the Churg-Strauss syndrome.

Authors:  J L Faul; W G Kuschner
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

6.  Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

Authors:  P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

7.  Wegener granulomatosis involving the pterygopalatine fossa: an unusual case of trigeminal neuropathy.

Authors:  Kathlyn Marsot-Dupuch; Sebastien Clement De Givry; Michel Ouayoun
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

8.  Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Authors:  M M Boomsma; D J Stearns-Kurosawa; C A Stegeman; E Raschi; P L Meroni; S Kurosawa; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

9.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

10.  Systemic vasculitis: a dual diagnosis?

Authors:  Eliza Gil; Pamela Lutalo; David D'Cruz
Journal:  BMJ Case Rep       Date:  2011-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.